within Pharmacolibrary.Drugs.ATC.J;

model J04AB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.04666666666666666,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.068,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007666666666666667,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Rifapentine is a long-acting rifamycin antibiotic used primarily in the treatment of tuberculosis (TB), including latent TB infection and active pulmonary TB. It acts by inhibiting DNA-dependent RNA polymerase in Mycobacterium tuberculosis. Rifapentine is approved by several regulatory agencies including the FDA and is commonly used in combination regimens with other anti-tuberculous agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects, both male and female, following oral administration.</p><h4>References</h4><ol><li>Jennifer E Hibma, Kendra K Radtke, Susan E Dorman, Amina Jindani, Kelly E Dooley, Marc Weiner, Helen M McIlleron, Radojka M Savic,Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.,American journal of respiratory and critical care medicine,2020<a href='https://pubmed.ncbi.nlm.nih.gov/32412342/'>https://pubmed.ncbi.nlm.nih.gov/32412342/</a></li><li>April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, Andrew Vernon, Payam Nahid, Rodney Dawson, Kelly E Dooley, Ian Sanne, Ziyaad Waja, Lerato Mohapi, Anthony T Podany, Wadzanai Samaneka, Rada M Savic, John L Johnson, Grace Muzanyi, Umesh G Lalloo, Kia Bryant, Erin Sizemore, Nigel Scott, Susan E Dorman, Richard E Chaisson, Susan Swindells,Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2023<a href='https://pubmed.ncbi.nlm.nih.gov/36041016/'>https://pubmed.ncbi.nlm.nih.gov/36041016/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J04AB05;
